Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI Doctor's helper: can a chatbot improve emergency brain care?

NCT ID NCT07626229

Knowledge-focused Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study tests whether an AI tool called Xuanwu-NeuroAid 2.0 can help emergency room doctors better diagnose and treat patients with sudden brain or nerve problems. About 1,360 adults with acute neurological symptoms will be randomly assigned to receive either standard care or care assisted by the AI. The AI provides suggestions, but doctors make all final decisions. The main goal is to see if AI assistance reduces diagnostic errors, unplanned return visits, or harm within 30 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Xuanwu-NeuroAid 2.0 (a large language model AI tool)
What this could lead to
If successful, this could show that AI assistance improves diagnostic accuracy and reduces errors in emergency neurology, potentially leading to better patient outcomes.
What could go wrong
This is an early-stage trial testing a new AI tool. The AI may not improve diagnosis, could introduce errors, or may not be practical in real-world emergency settings. Doctors remain responsible for all decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,381 people

The number who actually took part.

Started

Jun 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years; * Presentation to the emergency neurology service with acute neurological symptoms; * Written informed consent provided by the patient or a legally authorized representative. Exclusion Criteria: * Presentation primarily for trauma; * Pregnancy; * Requiring immediate life-saving interventions; * Estimated life expectancy of less than 30 days; * Participation in another clinical trial within the previous 30 days or in a trial that could interfere with the study or outcome assessment; * Any condition that, in the opinion of the investigators, would interfere with the conduct of the trial or the interpretation of the results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nervous system diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease nervous system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nervous system diseases

Contacts and locations

Locations

  • Liuyang Jili Hospital

    Guankou, Hunan, 410300, China

  • Nanyang Nanshi Hospital

    Nanyang, Henan, 473000, China

  • Xuanwu Hospital，Capital Medical University

    Beijing, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.